Mats Wahlgren's work with new drug Sevuparin featured in Ciennce
New data published after trials using the anti Malarial drug Sevuparin have been accepted by the journal PlosOne, and featured in an article in Ciennce this month. MTC's Mats Wahlgren has run the studies together with Anna Leitgeb at Modus Therapeutics AB and Arjen Dondorp at the Oxford-Mahidol Unit in Thailand.
Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria.
PLoS ONE 2017 ;12(12):e0188754